In the second of a three-part series, topics such as drug approvals and shortages, therapeutic interchanges, and pharmacoeconomic assessments are discussed.
You are here
P&T® Journal contents for December 2009
An Interview Series with Members of the ASHP Expert Panel on Formulary Management. Part 2: J. Russell May, PharmD
Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths
Research has addressed individual ADHD drugs, but few head-to-head trials have been conducted. In a meta-analysis of 32 trials, variable drug effects were noted.
Valuable Insight or Government Intrusion?
Comparative effectiveness research has the potential to direct health care spending toward effective therapies and to assist P&T committees. However, some experts question its potential benefit, and others say that collecting the evidence might not be that easy.
Pay-for-Delay and Authorized Generics Back in the Spotlight
Blogs in health care and law are abuzz over a bill to restrict drug companies from “pay-for-delay” patent settlements that postpone the introduction of generics.
Parenteral nicardipine for hypertension, omalizumab for asthma, and acquired coagulopathy from the use of topical bovine thrombin are discussed.
Drugs discussed include ofatumumab, pazopanib, and a C1 esterase inhibitor.